FDA Releases Draft Guidance for Early-Phase Solid Tumor Drug Trials

The U.S. FDA has issued new draft guidance for sponsors conducting early-phase first-in-human (FIH) studies for investigational drugs and biologics targeting solid tumors. This initiative, part of Operation TrialBlazer, aims to streamline and accelerate the development of new cancer treatments.